Physician profile
Mark A Spurlin
NPI 1275552168
$3,405.41
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $483 · 2021: $1,021 · 2022: $616 · 2023: $430 · 2024: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $883.51 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $784.00 | 2019-2024 | Linzess, Creon, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $354.08 | 2019-2023 | Gattex, Entyvio |
| Janssen Biotech, INC. | $342.74 | 2019-2023 | Stelara |
| Pfizer INC. | $102.53 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $90.99 | 2019-2022 | |
| Braintree Laboratories, INC. | $89.42 | 2019-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $85.14 | 2020-2022 | |
| Gilead Sciences, INC. | $82.76 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $81.96 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $80.85 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $75.23 | 2024 | |
| Qol Medical, LLC | $62.48 | 2022-2023 | Sucraid |
| Redhill Biopharma INC. | $37.54 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $32.46 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $21.88 | 2022 | |
| Medtronic, INC. | $19.41 | 2021 | |
| Daiichi Sankyo INC. | $18.77 | 2019 | |
| Shionogi INC | $17.87 | 2020 | |
| Genzyme Corporation | $17.30 | 2023 | |
| Portola Pharmaceuticals, LLC | $17.22 | 2019 | |
| Ambu INC. | $15.86 | 2021 | |
| Boston Scientific Corporation | $15.61 | 2024 | |
| Cook Medical LLC | $15.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.90 | 2019 | |
| Ucb, INC. | $12.49 | 2019 | |
| Merck Sharp & Dohme LLC | $12.04 | 2019 | |
| Evoke Pharma, INC. | $11.67 | 2021 | |
| Allergan, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Spurlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.